EXHIBIT A

FORM NRC-313M (8-78) 10 CFR 35	U.S. NUCLEAR REGULATORY COMMISSION APPLICATION FOR MATERIALS LICENSE – MEDICAL	Approved: GAO R0557

INSTRUCTIONS – *Complete Items 1 through 26 if this is an initial application or an application for renewal of a license. Use supplemental sheets where necessary. Item 26 must be completed on all applications and signed. Retain one copy. Submit original and one copy of entire application to : Director, Office of Nuclear Materials Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555. Upon approval of this application, the applicant will receive a Materials License. An NRC Materials License is issued in accordance with the general requirements contained in Title 10, Code of Federal Regulations, Part 30, and the Licensee is subject to Title 10, Code of Federal Regulations, Parts 19, 20 and 35 and the license fee provision of Title 10, Code of Federal Regulations, Part 170. The license fee category should be stated in Item 26 and the appropriate fee enclosed.*

1.a. NAME AND MAILING ADDRESS OF APPLICANT *(institution, firm, clinic, physician, etc.)* INCLUDE ZIP CODE

WOODLAND MEDICAL GROUP
22341 West Eight Mile Road
Detroit, Michigan 48219

TELEPHONE NO.: AREA CODE (313) 538-4700

1.b. STREET ADDRESS(ES) AT WHICH RADIOACTIVE MATERIAL WILL BE USED *(If different from 1.a.)* INCLUDE ZIP CODE

22341 West Eight Mile Road
Detroit, Michigan 48219
and
41935 West Twelve Mile Road
Novi, Michigan 48050

2. PERSON TO CONTACT REGARDING THIS APPLICATION

William D. Hack, M.P.H.

TELEPHONE NO.: AREA CODE (313) 662-3197

3. THIS IS AN APPLICATION FOR: *(Check appropriate item)*

a. ☐ NEW LICENSE
b. ☐ AMENDMENT TO LICENSE NO. _____
c. ☒ RENEWAL OF LICENSE NO. 21-13255-01

4. INDIVIDUAL USERS *(Name individuals who will use or directly supervise use of radioactive material. Complete Supplements A and B for each individual.)*

Harold Daitch, M.D.
Richard Small, M.D.
Seymour Mirkes, M.D.

5. RADIATION SAFETY OFFICER (RSO) *(Name of person designated as radiation safety officer. If other than individual user, complete resume of training and experience as in Supplement A.)*

Harold Daitch, M.D.

6.a. RADIOACTIVE MATERIAL FOR MEDICAL USE

RADIOACTIVE MATERIAL LISTED IN:	ITEMS DESIRED "X"	MAXIMUM POSSESSION LIMITS *(In millicuries)*
10 CFR 31.11 FOR IN VITRO STUDIES	X	3
10 CFR 35.100, SCHEDULE A, GROUP I	X	AS NEEDED
10 CFR 35.100, SCHEDULE A, GROUP II	X	AS NEEDED
10 CFR 35.100, SCHEDULE A, GROUP III	X	2000
10 CFR 35.100,SCHEDULE A, GROUP IV	X	AS NEEDED
10 CFR 35.100, SCHEDULE A, GROUP V		
10 CFR 35.100, SCHEDULE A, GROUP VI		

ADDITIONAL ITEMS:	MARK ITEMS DESIRED "X"	MAXIMUM POSSESSION LIMITS *(In millicuries)*
IODINE-131 AS IODIDE FOR TREATMENT OF HYPERTHYROIDISM		
PHOSPHORUS-32 AS SOLUBLE PHOSPHATE FOR TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA AND BONE METASTASES		
PHOSPHORUS-32 AS COLLOIDAL CHROMIC PHOSPHATE FOR INTRACAVITARY TREATMENT OF MALIGNANT EFFUSIONS.		
GOLD-198 AS COLLOID FOR INTRACAVITARY TREATMENT OF MALIGNANT EFFUSIONS.		
IODINE-131 AS IODIDE FOR TREATMENT OF THYROID CARCINOMA		
XENON-133 AS GAS OR GAS IN SALINE FOR BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES.	X	200

RECEIVED
JAN 31 1985
REGION III

6.b. RADIOACTIVE MATERIAL FOR USES NOT LISTED IN ITEM 6.a. *(Sealed sources up to 3 mCi used for calibration and reference standards are authorized under Section 35.14(d), 10 CFR Part 35 , and NEED NOT BE LISTED.)*

ELEMENT AND MASS NUMBER	CHEMICAL AND/OR PHYSICAL FORM	MAXIMUM NUMBER OF MILLICURIES OF EACH FORM	DESCRIBE PURPOSE OF USE
Americium--241	sealed source	12	Imaging Marker Siemens S/N 313793-X-1

8505030205 850423
REG3 LIC30
21-13255-01 PDR

RECEIVED
1985 FEB 12 AM 10:26
U.S. NRC
OFFICE OF RADIATION PROTECTION

Applicant Feb 12 III
Check No. 16784
Amount $370
Type
Date Check Rec'd 2/12/85
Received By

FORM NRC-313M (8-78)

CONTROL NO. 78231

JAN 31 1985

INFORMATION REQUIRED FOR ITEMS 7 THROUGH 23

For Items 7 through 23, check the appropriate box(es) and submit a detailed description of all the requested information. Begin each item on a separate sheet. Identify the item number and the date of the application in the lower right corner of each page. If you indicate that an appendix to the medical licensing guide will be followed, do not submit the pages, but specify the revision number and date of the referenced guide: Regulatory Guide 10.8 , Rev. 1* Date: 1980

7. MEDICAL ISOTOPES COMMITTEE N/A	**15. GENERAL RULES FOR THE SAFE USE OF RADIOACTIVE MATERIAL** *(Check One)*
Names and Specialties Attached; and	X Appendix G Rules Followed; or
Duties as in Appendix B; or *(Check One)*	Equivalent Rules Attached
Equivalent Duties Attached	**16. EMERGENCY PROCEDURES** *(Check One)*
8. TRAINING AND EXPERIENCE	X Appendix H Procedures Followed; or
Supplements A & B Attached for Each Individual User; and	Equivalent Procedures Attached
Supplement A Attached for RSO.	**17. AREA SURVEY PROCEDURES** *(Check One)*
9. INSTRUMENTATION *(Check One)*	X Appendix I Procedures Followed; or Note Modification
X Appendix C Form Attached; or	Equivalent Procedures Attached
List by Name and Model Number	**18. WASTE DISPOSAL** *(Check One)*
10. CALIBRATION OF INSTRUMENTS	X Appendix J Form Attached; or
X Appendix D Procedures Followed for Survey Instruments; or *(Check One)*	Equivalent Information Attached
Equivalent Procedures Attached; and	**19. THERAPEUTIC USE OF RADIOPHARMACEUTICALS** *(Check One)*
X Appendix D Procedures Followed for Dose Calibrator; or Note Modification *(Check One)*	X Appendix K Procedures Followed; or
Equivalent Procedures Attached	Equivalent Procedures Attached
11. FACILITIES AND EQUIPMENT	**20. THERAPEUTIC USE OF SEALED SOURCES**
X Description and Diagram Attached	Detailed Information Attached; and
12. PERSONNEL TRAINING PROGRAM	Appendix L Procedures Followed; or *(Check One)*
X Description of Training Attached	Equivalent Procedures Attached
13. PROCEDURES FOR ORDERING AND RECEIVING RADIOACTIVE MATERIAL	**21. PROCEDURES AND PRECAUTIONS FOR USE OF RADIOACTIVE GASES (e.g., Xenon – 133)**
X Detailed Information Attached	X Detailed Information Attached
14. PROCEDURES FOR SAFELY OPENING PACKAGES CONTAINING RADIOACTIVE MATERIALS *(Check One)*	**22. PROCEDURES AND PRECAUTIONS FOR USE OF RADIOACTIVE MATERIAL IN ANIMALS**
	Detailed Information Attached
X Appendix F Procedures Followed; or	**23. PROCEDURES AND PRECAUTIONS FOR USE OF RADIOACTIVE MATERIAL SPECIFIED IN ITEM 6.b**
Equivalent Procedures Attached	Detailed Information Attached

CONTROL NO. 78231

24. PERSONNEL MONITORING DEVICES

TYPE (Check appropriate box)			SUPPLIER	EXCHANGE FREQUENCY
a. WHOLE BODY	X	FILM	R.S. Landauer, Jr.	monthly
		TLD		
		OTHER (Specify)		
b. FINGER		FILM		
	X	TLD	R.S. Landauer, Jr.	monthly
		OTHER (Specify)		
c. WRIST		FILM		
		TLD		
		OTHER (Specify)		

d. OTHER (Specify)

Bioassays will not be performed since all I-131 use as iodide for the treatment of hyperthyroidism is in capsule form.

Appendix O of regulatory Guide 10.8 (ALARA) will be followed.

25. FOR PRIVATE PRACTICE APPLICANTS ONLY

a. HOSPITAL AGREEING TO ACCEPT PATIENTS CONTAINING RADIOACTIVE MATERIAL

NAME OF ~~HOSPITAL~~ CLINIC: WOODLAND MEDICAL GROUP, P.C.

MAILING ADDRESS: 22341 W. EIGHT MILE RD.

CITY: DETROIT. STATE: MI ZIP CODE: 48219

b. ATTACH A COPY OF THE AGREEMENT LETTER SIGNED BY THE HOSPITAL ADMINISTRATOR.

c. WHEN REQUESTING THERAPY PROCEDURES, ATTACH A COPY OF RADIATION SAFETY PRECAUTIONS TO BE TAKEN AND LIST AVAILABLE RADIATION DETECTION INSTRUMENTS.

26. CERTIFICATE

(This item must be completed by applicant)

The applicant and any official executing this certificate on behalf of the applicant named in Item 1a certify that this application is prepared in conformity with Title 10, Code of Federal Regulations, Parts 30 and 35, and that all information contained herein, including any supplements attached hereto, is true and correct to the best of our knowledge and belief.

a. LICENSE FEE REQUIRED *(See Section 170.31, 10 CFR 170)*

(1) LICENSE FEE CATEGORY: 7.C. renewal

(2) LICENSE FEE ENCLOSED: $ 580.00

b. APPLICANT OR CERTIFYING OFFICIAL *(Signature)*: Harold J. Daitch MD

(1) NAME *(Type or Print)*: HAROLD J. DAITCH, M.D.

(2) TITLE: CHIEF - DEPT. OF DIAGNOSTIC IMAGING

c. DATE: JAN. 28, 1985

FORM NRC-313M (8-78)

CONTROL NO. 78231

PRIVACY ACT STATEMENT

Pursuant to 5 U.S.C. 552a(e)(3), enacted into law by section 3 of the Privacy Act of 1974 (Public Law 93-579), the following statement is furnished to individuals who supply information to the Nuclear Regulatory Commission on Form NRC-313M. This information is maintained in a system of records designated as NRC-3 and described at 40 Federal Register 45334 (October 1, 1975).

1. **AUTHORITY** Sections 81 and 161(b) of the Atomic Energy Act of 1954, as amended (42 U.S.C. 2111 and 2201(b)).

2. **PRINCIPAL PURPOSE(S)** The information is evaluated by the NRC staff pursuant to the criteria set forth in 10 CFR Parts 30-36 to determine whether the application meets the requirements of the Atomic Energy Act of 1954, as amended, and the Commission's regulations, for the issuance of a radioactive material license or amendment thereof.

3. **ROUTINE USES** The information may be used: (a) to provide records to State health departments for their information and use; and (b) to provide information to Federal, State, and local health officials and other persons in the event of incident or exposure, for their information, investigation, and protection of the public health and safety. The information may also be disclosed to appropriate Federal, State, and local agencies in the event that the information indicates a violation or potential violation of law and in the course of an administrative or judicial proceeding. In addition, this information may be transferred to an appropriate Federal, State, or local agency to the extent relevant and necessary for a NRC decision or to an appropriate Federal agency to the extent relevant and necessary for that agency's decision about you. A copy of the license issued will routinely be placed in the NRC's Public Document Room, 1717 H Street, N.W., Washington, D.C.

4. **WHETHER DISCLOSURE IS MANDATORY OR VOLUNTARY AND EFFECT ON INDIVIDUAL OF NOT PROVIDING INFORMATION** Disclosure of the requested information is voluntary. If the requested information is not furnished, however, the application for radioactive material license, or amendment thereof, will not be processed.

5. **SYSTEM MANAGER(S) AND ADDRESS** Director, Division of Fuel Cycle and Material Safety, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555.

CONTROL NO. 18231

TRAINING AND EXPERIENCE

NAME OF AUTHORIZED USER	AUTHORIZATION
Harold Daitch, M.D.	As currently listed on NRC License No. 21-13255-01.
Richard Small, M.D.	As currently listed on NRC License No. 21-13255-01.
Seymour Mirkes, M.D.	As currently listed on NRC License No. 21-13255-01.

CONTROL NO. 78231

WOODLAND MEDICAL GROUP
41935 West Twelve Mile Road
Novi, Michigan 48050

FACILITY DIAGRAM



CONTROL NO. 78231

ITEM 11

PERSONNELL TRAINING PROGRAM

I. Individuals who work in or frequent restricted areas will be instructed in the items specified in 10 CFR 19.12 at the time of initial employment and at least annually thereafter.

This instruction will include:

a. All terms of the license pertinent to radiation safety.

b. Areas where radioactive material is used or stored.

c. Potential hazards associated with radioactive material.

d. Radiological safety procedures appropriate to their respective duties.

e. Pertinent NRC regulations.

f. Rules and regulations of the license.

g. Obligation to report unsafe conditions to the Radiation Safety Officer.

h. Appropriate response to emergencies or unsafe conditions.

i. Right to be informed of their radiation exposure and bioassy results.

j. Locations where the license has been posted or make available notices, copies of pertinent regulations, and copies or pertinent licenses and license conditions (including applications and applicable correspondence,) as required by 10 CFR Part 19.

II. Individuals whose duties may require them to work in the vicinity of licensed material will be informed about radiation hazards and appropriate precautions at the time of initial employment and at least annually thereafter. This information will be provided initially at hospital employee orientation sessions and annually thereafter at in-service meetings.

CONTROL NO. 78231

APPENDIX C

INSTRUMENTATION

22341 West 8 Mile Rd.

1. Survey meters

   a. Manufacturer's name: Eberline

   Manufacturer's model number: E-120

   Number of instruments available: 1

   Minimum range: 0.0 mR/hr to 0.5 mR/hr

   Maximum range: 0.0 mR/hr to 50.0 mR/hr

   b. Manufacturer's name: Eberline *

   Manufacturer's model number: E-520

   Number of instruments available: 1

   Minimum range: 0.0 mR/hr to 0.2 mR/hr

   Maximum range: 0.0 mR/hr to 2000 mR/hr

   *Needed for high range with Mo-99/Tc-99m generator. Will be available when a generator is used. It will not be available if we elect not to use a generator and unit doses are used instead (Syncor).

2. Dose calibrator

   Manufacturer's name: Capintec

   Manufacturer's model number: CRC 10R

   Number of instruments available: 1

3. Instruments used for diagnostic procedures

Type of Instrument	Manufacturer's Name	Model No.
Gamma Camera	Siemens	ZLC 370
Gamma Camera	Searle	LEM
Thyroid Uptake System	Picker	Spectroscaler-4

4. Other (e.g., liquid scintillation counter, area monitor, velometer)

GM Survey Meter	Picker	M/N CDV-700

CONTROL NO. 7823

APPENDIX C

INSTRUMENTATION

22341 West 8 Mile Rd.

1. Survey meters

a. Manufacturer's name: Eberline

Manufacturer's model number: E-120

Number of instruments available: 1

Minimum range: 0.0 mR/hr to 0.5 mR/hr

Maximum range: 0.0 mR/hr to 50.0 mR/hr

b. Manufacturer's name: Eberline *

Manufacturer's model number: E-520

Number of instruments available: 1

Minimum range: 0.0 mR/hr to 0.2 mR/hr

Maximum range: 0.0 mR/hr to 2000 mR/hr

*Needed for high range with Mo-99/Tc-99m generator. Will be available when a generator is used. It will not be available if we elect not to use a generator and unit doses are used instead (Syncor).

2. Dose calibrator

Manufacturer's name: Capintec

Manufacturer's model number: CRC 10R

Number of instruments available: 1

3. Instruments used for diagnostic procedures

Type of Instrument	Manufacturer's Name	Model No.
Gamma Camera	Siemens	ZLC 370
Gamma Camera	Searle	LEM
Thyroid Uptake System	Picker	Spectroscaler-4

4. Other (e.g., liquid scintillation counter, area monitor, velometer)

GM Survey Meter	Picker	M/N CDV-700

CONTROL NO. 78231

APPENDIX C

INSTRUMENTATION

41935 West 12 Mile Rd.

1. Survey meters

a. Manufacturer's name: Eberline

Manufacturer's model number: E-120

Number of instruments available: 1

Minimum range: 0.0 mR/hr to 0.5 mR/hr

Maximum range: 0.0 mR/hr to 50.0 mR/hr

b. Manufacturer's name: Eberline *

Manufacturer's model number: E-520

Number of instruments available: 1

Minimum range: 0.0 mR/hr to 0.2 mR/hr

Maximum range: 0.0 mR/hr to 2000 mR/hr

*Needed for high range with Mo-99/Tc-99m generator. Will be available when a generator is used. It will not be available if we elect not to use a generator and unit doses are used instead (Syncor).

2. Dose calibrator

Manufacturer's name: Capintec

Manufacturer's model number: CRC-4

Number of instruments available: 1

3. Instruments used for diagnostic procedures

Type of Instrument	Manufacturer's Name	Model No.
Gamma Camera	G.E.	Maxi 4
Thyroid Uptake System	Ludlum	2600

4. Other (e.g., liquid scintillation counter, area monitor, velometer)

CONTROL NO. 78231

CALIBRATION OF SURVEY INSTRUMENTS

Check appropriate items.

__X__ 1. Survey instruments will be calibrated at least annually and following repair.

__X__ 2. Calibration will be performed at two points on each scale used for radiation protection purposes, i.e., at least up to 1 R/hr.

The two points will be approximately 1/3 and 2/3 of full scale. A survey instrument may be considered properly calibrated when the instrument readings are within ± 10 percent of the calculated or known values for each point checked. Readings within ± 20 percent are considered acceptable if a calibration chart, graph, or response factor is prepared, attached to the instrument, and used to interpret readings to within ± 10 percent. Also, when higher scales are not checked or calibrated, an appropriate precautionary note will be posted on the instrument.

3. Survey instruments will be calibrated

_____ a. By the manufacturer

_____ b. At the licensee's facility

(1) Calibration source

Manufacturer's name _____
Model no. _____
Activity in millicuries _____
or
Exposure rate at a specified distance _____
Accuracy _____
Traceability to primary standard _____

_____ (2) The calibration procedures in Section I of Appendix D will be used

or

_____ (3) The step-by-step procedures, including radiation safety procedures, are attached.

__X__ c. By a consultant or outside firm

(1) Name Medical Physics Consultants, Inc.

(2) Location Suite F-1, 3200 West Liberty, Ann Arbor, MI 48103

(3) Procedures and sources

__X__ have been approved by NRC and are on file in License No. 21-20153-01

_____ have been approved by an Agreement State; a copy of the Agreement State license, the procedures, and a description of the sources are attached, and the consultant's report will contain the information on

_____ the attached "Certificate of Instrument Calibration."
__X__ the consultant's reporting form as attached.

_____ are described in the attachment, and the consultant's report will contain the information on

_____ the attached "Certificate of Instrument Calibration."
_____ the consultant's reporting form as attached.

CONTROL NO. 78231

Medical Physics Consultants, Inc.

CERTIFICATE OF INSTRUMENT CALIBRATION

For: Hospital or Clinic

Instrument:

Manufacturer- Mfgr
Type- Type
Model Number- M/N
Serial Number- S/N

	Nuclide	Exposure Rate at Specified Distance	Calibration Accuracy
Calibration Source:	Cs-137	26.0 mR/h at 1 m	+/- 3% NBS

Calibration Data:

Scale	Exposure rate (mR/h)	Instrument reading (mR/h)	Exposure rate (mR/h)	Instrument reading (mR/h)

Comments: All instrument readings are within +/- 10%.
Drift check OK.

Calibrated by: _____ Date: 00-00-85

CONTROL NO. 78231

APPENDIX D

CALIBRATION OF INSTRUMENTS

Section 1

METHODS FOR CALIBRATION OF (X- AND GAMMA-RAY) SURVEY METERS, INCLUDING PROCEDURES, STANDARDS, AND FREQUENCY

A. Calibration of survey meters shall be performed with radionuclide sources.

1. The sources shall be approximate point sources.

2. The source activities or exposure rates at given distances shall be traceable by documented measurements to a standard source certified within 5 percent accuracy to the U.S. National Bureau of Standards (NBS) calibrations.

3. The frequency shall be at least annually and after servicing.

4. Each scale of the instrument shall be calibrated at least at two points located at approximately 1/3 and 2/3 of full scale.

5. The exposure rate measured by the instrument shall differ from the true exposure rate by less than 10 percent at the two points on each scale (read appropriate section of the instrument manual to determine how to make necessary adjustments to bring instrument into calibration). Readings within ±20 percent will be considered acceptable if a calibration chart, graph, or response factor is prepared, attached to the instrument, and used to interpret meter readings to within 10 percent for radiation protection purposes.

Note:

Sources of Cs-137, Ra-226, or Co-60* are appropriate for use in calibrations. Since these sources emit rather high-energy photons, they are not suitable for low-energy calibrations that may be required under special circumstances (see Item C below). The activity of the calibration standard should be sufficient to calibrate the survey meters on each scale to be used for radiation protection purposes. Scales up to 1 R/hr should be calibrated, but higher-range scales above 1 R/hr need not be calibrated when they will not be needed for radiation protection surveys. If there are higher ranges, they should at least be checked for operation and approximately correct response to radiation. Otherwise, a cautionary note that they have not been checked should be placed on the instrument.

B. A reference check source of long half-life, e.g., Cs-137 or Ra D and E, shall also be read at the time of the above calibration or as soon as the instrument is received from a calibration laboratory. The readings shall be taken with the check source placed in specific geometry relative to the detector. A reading of this reference check source should be taken:

1. Before each use and also after each survey to ensure that the instrument was operational during the survey.

2. After each maintenance and/or battery change.

3. At least quarterly.

If any reading with the same geometry is not within ±20 percent of the reading measured immediately after calibration, the instrument should be recalibrated (see Item A).

C. The instrument must be calibrated at lower energies if its response is energy dependent and if the instrument is to be used for quantitative measurements in the Xe-133 or Tc-99m energy ranges.

The calibration may be done either:

1. As in Item A above with calibrated standards of radionuclides at or near the desired energies, or

2. As a relative intercomparison with an energy-independent instrument and uncalibrated radionuclides.

Alternatively, the manufacturer's energy response curve(s) may be used to correct instrument readings appropriately when lower-energy radiation is monitored.

D. Records of the above Items A, B-2, B-3, and C must be maintained.

E. Use of Inverse Square Law and Radioactive Decay Law

1. A calibrated source will have a calibration certificate giving its exposure rate at a given distance.

*Minimum activities of typical sources are 85 mCi of Cs-137, 21 mCi of Co-60, and 34 mCi of Ra-226 (to give at least 700 mR/hr at 20 cm).

CONTROL

or its activity, measured on a specified date by the manufacturer or NBS.

a. The Inverse Square Law may be used with any point source to calculate the exposure rate at other distances.

b. The Radioactive Decay Law may be used to calculate the exposure rates or source activities at times other than the calibration date.

2. Inverse Square Law

Consider a "point"* source of radiation at position S, as shown in Figure D-1. Then, the relationship between exposure rates R_1 and R_2 at detector positions P_1 and P_2, which are at distances D_1 and D_2 from S, respectively, is given by the following equation:

$$R_2 = \frac{D_1^2}{D_2^2} \times R_1,$$

where R_1 and R_2 are exposure rates in the same units (e.g., mR/hr, R/hr), and D_1 and D_2 are the distances in Figure D-1 in the same units (e.g., m, cm, ft).



Figure D-1

3. Radioactive Decay Law

Exposure rate t units of time after specified calibration date

$$R_t = R_o \times e^{-\left[\frac{0.693}{T_{1/2}} \times t\right]}$$

where

R_o and R_t are in the same units (e.g., mR/hr or R/hr).

R_o is exposure rate on the specified calibration date.

R_t is exposure rate t units of time later.

$T_{1/2}$ and t are in the same units (years, months, days, etc.).

$T_{1/2}$ is radionuclide half-life.

t is number of units of time elapsed between calibration and present time.

4. *Example*: Source output is given by calibration certificate as 100 mR/hr at 1 foot on March 10, 1975. Radionuclide half-life is 5.27 years.

Question: What is the output at 3 feet on March 10, 1977 (2.0 years)?

a. Output at 1 foot, 2.0 years after calibration date:

$$R = 100 \text{ mR/hr} \times e^{-\frac{(0.693 \times 2.0)}{5.3}}$$

$$= 100 \times 0.77 = 77 \text{ mR/hr at 1 foot on March 10, 1977.}$$

b. Output at 3 feet, 2.0 years after calibration date:

$$R_{3 \text{ feet}} = \frac{(1 \text{ foot})^2}{(3 \text{ feet})^2} \times 77 \text{ mR/hr}$$

$$= \frac{1}{9} \times 77 = 8.6 \text{ mR/hr at 3 feet, 2.0 years after calibration.}$$

*A source may be considered a "point" source when the source and the radiation detector are small, in any dimension, compared to the distances at which radiation is to be measured. The center of the detector should be at distances D_1 or D_2 as shown in Figure D-1.

CONTROL NO. 78031

CALIBRATION OF DOSE CALIBRATOR

A. Sources Used for Linearity Test

(Check as appropriate)

__x__ First elution from new Mo-99/Tc-99m generator

or

__x__ Other* (specify) If generators are not in use, a source of Tc-99m with activity equivalent to the maximum activity assayed for clinical situations will be used.

B. Sources Used for Instrument Accuracy and Constancy Tests

Radionuclide	Suggested Activity (mCi)	Activity (mCi)	Accuracy
Co-57	3-5	One millicurie or more	+/- 5%
Ba-133	0.1-0.5	100 microcuries or more	+/- 5%
Cs-137	0.1-0.2	100 microcuries or more	+/- 5%
Ra-226	1-2		

C. __x*__ The procedures described in Section 2 of Appendix D will be used for calibration of the dose calibrator

or

_____ Equivalent procedures are attached.

*For licensees who are not authorized for Mo-99/Tc-99m generators, activity must be equivalent to the highest activity used.

*In addition, to the test procedures outlined in Appendix D-Section 2 for instrument linearity, we would like to add, as an option, the test procedure for instrument linearity using a device called Calicheck from Calcorp, Inc.. The manufacturer's instructions for use as revised on March 2, 1982, will be followed. Test results will be recorded and retained for inspection. Corrective action as stated in our License application will be followed if unacceptable linearity is demonstrated.

CONTROL NO. 78231

APPENDIX D (Continued)

Section 2

METHODS FOR CALIBRATION OF DOSE CALIBRATOR*

All radiopharmaceuticals must be assayed for activity to an accuracy of 10 percent. The most common instrument for accomplishing this is an ionization-type dose calibrator. The instrument must be checked for accurate operation at the time of installation and periodically thereafter.

A. Test for the following:

1. Instrument constancy (daily)
2. Instrument accuracy (at installation and annually thereafter)
3. Instrument linearity (at installation and quarterly thereafter)
4. Geometrical variation (at installation)

B. After repair or adjustment of the dose calibrator, repeat all the appropriate tests listed above (dependent upon the nature of the repairs).

C. Test for Instrument Constancy

Instrument constancy means that there is reproducibility, within a stated acceptable degree of precision, in measuring a constant activity over time. Assay at least one relatively long-lived reference source such as Cs-137, Co-57,** or Ra-226** using a reproducible geometry before each day's use of the instrument. Preferably, at least two reference sources (for example, 3-5 mCi of Co-57 and 100-200 μCi of Cs-137 or 1-2 mg Ra-226 (with appropriate decay corrections) will be alternated each day of use to test the instrument's performance over a range of photon energies and source activities.

1. Assay each reference source using the appropriate instrument setting (i.e., Cs-137 setting for Cs-137).
2. Measure background level at same instrument setting, or check that automatic background subtraction is operating properly when blanks are inserted in the calibrator.
3. Calculate net activity of each source subtracting out background level.
4. For each source, plot net activity versus the day of the year on semilog graph paper.
5. Log the background levels.
6. Indicate the predicted activity of each source based on decay calculations and the ±5 percent limits on the graph.
7. Repeat the procedure used for the Cs-137 source for all the commonly used radionuclide settings.
8. Variations greater than ±5 percent from the predicted activity indicate the need for instrument repair or adjustment.
9. Investigate higher than normal background levels to determine their origin and to eliminate them if possible by decontamination, relocation, etc.

D. Inspect the instrument on a quarterly basis to ascertain that the measurement chamber liner is in place and that instrument zero is properly set (see manufacturer's instructions).

E. Test of Instrument Linearity

The linearity of a dose calibrator should be ascertained over the entire range of activities employed. This test will use a vial of Tc-99m whose activity is equivalent to the maximum anticipated activity to be assayed (e.g., the first elution from a new generator).

1. Assay the Tc-99m vial in the dose calibrator, and subtract background level to obtain net activity in millicuries.
2. Repeat step 1 at time intervals of 6, 24, 30, and 48 hours after the initial assay.
3. Using the 30-hour activity measurement as a starting point, calculate the predicted activities at 0, 6, 24, and 48 hours using the following table:

---

* See ANSI N42.13-1978, "Calibration and Usage of Dose Calibrator Ionization Chambers for the Assay of Radionuclides" (American National Standards Institute, Inc., 1430 Broadway, New York, N.Y. 10018).

** Co-57 and Ra-226 are not subject to NRC licensing; the respective State agency should be consulted to determine its requirements for possessing this material.

CONTROL NO. 78231

Assay Time* (hr)	Correction Factor
0	31.633
6	15.853
24	1.995
30	1
48	0.126

Example: If the net activity measured at 30 hours was 15.625 mCi, the calculated activities for 6 and 48 hours would be 15.625 mCi x 15.853 = 247.7 mCi and 15.625 mCi x 0.126 = 1.97 mCi, respectively.

4. On log-log coordinate paper, plot the measured net activity (for each time interval) versus the calculated activity (for the same time interval).

5. The activities plotted should be within ±5 percent of the calculated activity if the instrument is linear and functioning properly. Errors greater than ±5 percent indicate the need for repair or adjustment of the instrument.

6. If instrument linearity cannot be corrected, it will be necessary in routine assays to use either (a) an aliquot of the eluate that can be accurately measured or (b) the graph constructed in step 4 to relate measured activities to calculated activities.

F. Test for Geometrical Variation

There may be significant geometrical variation in activity measured as a function of sample volume or configuration, depending on the volume and size of the ionization chamber used in the dose calibrator. The extent of geometrical variation should be ascertained for commonly used radionuclides and appropriate correction factors computed if variations are significant, i.e., greater than ±2 percent. (Even though correction factors may be provided by the manufacturer, the accuracy of these should be checked.) When available from the manufacturer, certified data on geometrical variations may be used in lieu of these measurements.

To measure variation with volume of liquid, a 30-cc vial containing 2 mCi of Co-57 or other appropriate radionuclide in a volume of 1 ml will be used.

1. Assay vial at the appropriate instrument setting, and subtract background level to obtain net activity.

2. Increase the volume of liquid in the vial in steps to 2, 4, 8, 10, 20, and 25 ml by adding the appropriate amount of water or saline. After each addition, gently shake vial to mix contents and assay as in step 1. (Follow good radiation safety practices to avoid contamination and to minimize radiation exposure.)

3. Select one volume as a standard (such as the volume of reference standard used in performing the test for instrument accuracy), and calculate the ratio of measured activities for each volume to the reference volume activity. This represents the volume correction factor (CF).

Example: If activities of 2.04, 2.02, and 2.00 mCi are measured for 4, 8, and 10 ml volumes and 10 ml is the reference volume selected,

$$4 \text{ ml Volume CF} = \frac{2.00}{2.04} = 0.98$$

4. Plot the correction factors against the volume on linear graph paper. Use this graph to select the proper volume correction factors for routine assay of that radionuclide.

5. The true activity of a sample is calculated as follows:

True Activity = Measured Activity x Correction Factor

where the correction factor used is for the same volume and geometrical configuration as the sample measured.

6. Similarly, the same activity of Co-57 in a syringe may be compared with that of 10 ml in a 30-cc vial, and a correction factor may be calculated.

7. It should be noted that differences of 200 percent in dose calibrator readings between glass and plastic syringes have been observed for lower-energy radionuclides such as I-125, which should be assayed in a dose calibrator only if the reliability of such an assay can be established. Glass tubes and syringes may also vary enough in thickness to cause significant errors in assaying I-125. Hence, adequate correction factors must be established.

An alternative to providing syringe calibration factors is to simply assay the stock vial before and after filling the syringe. The activity in the syringe is then the difference in the two readings (with a volume correction if significant).

G. Test for Instrument Accuracy

Check the accuracy of the dose calibrator for several radionuclides, including Cs-137, Co-57, and Ba-133, using appropriate reference standards whose activities have been calibrated by comparisons with standard sources that have been assayed by NBS and documented.

*Assay times should be measured in whole hours and correction factors should be used to the third decimal place as indicated. The more recent half-life of $T_{1/2}$ = 6.02 hours has been used in calculating these correction factors.

CONTROL NO. 78231

The activity levels of the reference sources used should approximate those levels normally encountered in clinical use (e.g., Co-57, 3-5 millicuries) giving adequate attention to source configuration. Identify in your application the three sources that you will use. State nuclide, activity, and calibration accuracy. The lower-energy reference standards (Tc-99m, Xe-133, I-125) must be in vials with the same thickness of glass as the actual samples to be measured for best accuracy.

1. Assay the reference standard in the dose calibrator at the appropriate setting, and subtract the background level to obtain the net activity.

2. Repeat step 1 for a total of 3 determinations, and average results.

3. The average activity determined in step 2 should agree with the certified activity of the reference source within ±5 percent after decay corrections.

4. Repeat the above steps for other commonly used radionuclides for which adequate reference standards are available.

5. Keep a log of these calibration checks.

6. Calibration checks that do not agree within ±5 percent indicate that the instrument should be repaired or adjusted. If this is not possible, a calibration factor should be calculated for use during routine assays of radionuclides.

7. At the same time the instrument is being initially calibrated at the licensee's facility with the reference standards, place a long-lived source in the calibrator, set the instrument, in turn, at the various radionuclide settings used (Cs-137, I-131, Tc-99m, I-125, etc.), and record the readings. These values may later be used to check instrument calibration at each setting (after correcting for decay of the long-lived source) without requiring more reference standards. Keep a log of these initial and subsequent readings.

CONTROL NO. 78231

WOODLAND MEDICAL GROUP
22341 West Eight Mile Road
Detroit, Michigan 48219

FACILITY DIAGRAM



CONTROL NO. 7 8 2 3 1

ITEM 11

APPENDIX E

PROCEDURES FOR ORDERING AND ACCEPTING DELIVERY OF RADIOACTIVE MATERIAL

1. The Supervisory Nuclear Medicine Technologist will place all orders for radioactive materials and will ensure that the requested materials and quantities are authorized by the license and that possession limits are not exceeded.

2. A system for ordering and receiving radioactive materials will be established and maintained. The system will consist minimally of the following.

   a. Ordering of routinely used materials

      (1) Written records that identify the isotope, compound, activity levels, and supplier, etc., will be used.

      (2) The written records will be referenced when opening or storing radioactive shipment.

   b. Ordering of specially used materials (e.g., therapeutic uses)

      (1) A written request* will be obtained from the physician who will perform the procedure.

      (2) Persons ordering the materials will reference the physician's written request when placing the order. The physician's request will indicate isotope, compound, activity level, etc.

      (3) The physician's written request will be referenced when receiving, opening, or storing the radioactive material.

   c. It is essential that written records* be maintained for all ordering and receipt procedures.

3. During normal working hours, carriers will be instructed to deliver radioactive packages directly to the Nuclear Medicine Department.

4. During off-duty hours, security personnel or other designated individuals will accept delivery of radioactive packages in accordance with the procedures outlined in the sample memorandum below.

*In the case of special orders, the physician's written request and appropriate shipping/receipt records will be referenced and the dose assayed prior to its administration.

**SAMPLE MEMORANDUM

MEMORANDUM FOR: Security Personnel

FROM: Facility Administrator

SUBJECT: RECEIPT OF PACKAGES CONTAINING RADIOACTIVE MATERIAL

Any package containing radioactive material that arrives between 4:30 p.m. and 7:00 a.m. or on Sundays shall be signed for by the Security Guard on duty and taken immediately to the Nuclear Medicine Department. Unlock the door, place the package on top of the counter immediately to the right of the door, and re-lock the door.

If the package is wet or appears to be damaged immediately contact the Radiation Safety Officer. Ask the carrier to remain until it can be determined that neither he nor the delivery vehicle is contaminated.

**RADIATION SAFETY OFFICER _____

**OFFICE PHONE _____

**HOME PHONE _____

**On the actual memo that is used, this information will be filled in and updated as necessary.

CONTROL NO. 78231

APPENDIX F

PROCEDURES FOR SAFELY OPENING PACKAGES CONTAINING RADIOACTIVE MATERIAL

1. Special requirements will be followed for packages containing quantities of radioactive material in excess of the Type A quantity limits as specified in paragraphs 20.205(a)(1) and (c)(1) of 10 CFR Part 20 (more than 20 Ci for Mo-99 and Tc-99m). They will be monitored for surface contamination and external radiation levels within 3 hours after receipt if received during working hours or within 18 hours if received after working hours, in accordance with the requirements of paragraphs 20.205(a) through (c). All shipments of liquids greater than exempt quantities will be tested for leakage. The NRC Regional Office will be notified in accordance with the regulations if removable contamination exceeds 0.01 μCi/100 cm^2 or if external radiation levels exceed 200 mR/hr at the package surface or 10 mR/hr at 3 feet (or 1 m).

2. For all packages, the following additional procedures for opening packages will be carried out:

   a. Put on gloves to prevent hand contamination.

   b. Visually inspect package for any sign of damage (e.g., wetness, crushed). If damage is noted, stop procedure and notify Radiation Safety Officer.

   c. Measure exposure rate at 3 feet (or 1 m) from package surface and record. If >10 mR/hr, stop procedure and notify Radiation Safety Officer.

   d. Measure surface exposure rate and record. If >200 mR/hr, stop procedure and notify Radiation Safety Officer.

   e. Open the package with the following precautionary steps:

      (1) Open the outer package (following manufacturer's directions, if supplied) and remove packing slip.

      (2) Open inner package and verify that contents agree with those on packing slip. Compare requisition,* packing slip, and label on bottle.

      (3) Check integrity of final source container (i.e., inspect for breakage of seals or vials, loss of liquid, and discoloration of packaging material).

      (4) Check also that shipment does not exceed possession limits.

   f. Wipe external surface of final source container and remove wipe to low background area. Assay the wipe and record amount of removable radioactivity (e.g., μCi/100 cm^2, etc.). Check wipes with a thin-end-window G-M survey meter, and take precautions against the spread of contamination as necessary.

   g. Monitor the packing material and packages for contamination before discarding.

      (1) If contaminated, treat as radioactive waste.

      (2) If not contaminated, obliterate radiation labels before discarding in regular trash.

3. Maintain records of the results of checking each package, using "Radioactive Shipment Receipt Record" (see next page) or a form containing the same information.

---

*In the case of special orders (e.g., therapy doses), also compare with physician's written request.

CONTROL NO. 78231

APPENDIX G

GENERAL RULES FOR SAFE USE OF RADIOACTIVE MATERIAL

1. Wear laboratory coats or other protective clothing at all times in areas where radioactive materials are used.

2. Wear disposable gloves at all times while handling radioactive materials.

3. Monitor hands and clothing for contamination after each procedure or before leaving the area.

4. Always use syringe shields for routine preparation of patient doses and administration to patients, except in circumstances such as pediatric cases when their use would compromise the patient's well-being. In these exceptional cases, use other protective methods such as remote delivery of the dose (e.g., through use of a butterfly valve).

5. a. Do not eat, drink, smoke, or apply cosmetics in any area where radioactive material is stored or used.

   b. Do not store food, drink, or personal effects with radioactive material.

6. a. Assay each patient dose in the dose calibrator prior to administration. Do not use any doses that differ from the prescribed dose by more than 10 percent.

   b. For therapeutic doses, also check the patient's name, the radionuclide, the chemical form, and the activity vs. the order written by the physician who will perform the procedure.

7. Wear personnel monitoring devices (film badge or TLD) at all times while in areas where radioactive materials are used or stored. These devices should be worn at chest or waist level. Personnel monitoring devices when not being worn to monitor occupational exposures should be stored in a designated low background area.

8. Wear TLD finger badges during elution of generator and preparation, assay, and injection of radiopharmaceuticals.

9. Dispose of radioactive waste only in specially designated and properly shielded receptacles.

10. Never pipette by mouth.

11. Survey generator, kit preparation, and injection areas for contamination after each procedure or at the end of the day. Decontaminate if necessary.

12. Confine radioactive solutions in covered containers plainly identified and labeled with name of compound, radionuclide, date, activity, and radiation level, if applicable.

13. Always transport radioactive material in shielded containers.

CONTROL NO. 78231

APPENDIX H

EMERGENCY PROCEDURES

Minor Spills

1. NOTIFY: Notify persons in the area that a spill has occurred.

2. PREVENT THE SPREAD: Cover the spill with absorbent paper.

3. CLEAN UP: Use disposable gloves and remote handling tongs. Carefully fold the absorbent paper and pad. Insert into a plastic bag and dispose of in the radioactive waste container. Also insert into the plastic bag all other contaminated materials such as disposable gloves.

4. SURVEY: With a low-range, thin-window G-M survey meter, check the area around the spill, hands, and clothing for contamination.

5. REPORT: Report incident to the Radiation Safety Officer.

Major Spills

1. CLEAR THE AREA: Notify all persons not involved in the spill to vacate the room.

2. PREVENT THE SPREAD: Cover the spill with absorbent pads, but do not attempt to clean it up. Confine the movement of all personnel potentially contaminated to prevent the spread.

3. SHIELD THE SOURCE: If possible, the spill should be shielded, but only if it can be done without further contamination or without significantly increasing your radiation exposure.

4. CLOSE THE ROOM: Leave the room and lock the door(s) to prevent entry.

5. CALL FOR HELP: Notify the Radiation Safety Officer immediately.

6. PERSONNEL DECONTAMINATION: Contaminated clothing should be removed and stored for further evaluation by the Radiation Safety Officer. If the spill is on the skin, flush thoroughly and then wash with mild soap and lukewarm water.

RADIATION SAFETY OFFICER: _____*
OFFICE PHONE: _____
HOME PHONE: _____

ALTERNATE NAMES AND TELEPHONE NUMBERS DESIGNATED BY RADIATION SAFETY OFFICER:

_____
_____
_____

*The appropriate information for your facility should be supplied in these blanks when posting these procedures or submitting them with the application.

CONTROL NO. 78231

APPENDIX I

AREA SURVEY PROCEDURES

1. All elution, preparation, and injection areas will be surveyed daily with an appropriately low-range survey meter and decontaminated if necessary.*

2. Laboratory areas where only small quantities of radioactive material are used (less than 200 μCi) will be surveyed monthly.

3. Waste storage areas and all other laboratory areas will be surveyed weekly.

4. The weekly ahd monthly surveys will consist of:

   a. A measurement of radiation levels with a survey meter sufficiently sensitive to detect 0.1 mR/hr.

   b. A series of wipe tests to measure contamination levels. The method for performing wipe tests will be sufficiently sensitive to detect 200 dpm per 100 cm^2 for the contaminant involved. Wipes of elution and preparation areas or other "high background" areas will be removed to a low background area for measurement.

5. A permanent record will be kept of all survey results, including negative results. The record will include:

   a. Location, date, and identification of equipment used, including the serial number and pertinent counting efficiencies.

   b. Name of person conducting the survey.

   c. Drawing of area surveyed, identifying relevant features such as active storage areas, active waste areas, etc.

   d. Measured exposure rates, keyed to location on the drawing (point out rates that require corrective action).

   e. Detected contamination levels, keyed to locations on drawing.

   f. Corrective action taken in the case of contamination or excessive exposure rates, reduced contamination levels or exposure rates after corrective action, and any appropriate comments.

6. Area will be cleaned if the contamination level exceeds 200 dpm/100 cm^2.

*For daily surveys where no abnormal exposures are found, only the date, the identification of the person performing the survey, and the survey results will be recorded.

Modification: Items 4b. and 6. should be modified to read that, "Any areas indicating removable contamination upon wipe testing, will be cleaned." (eliminating the 200 DPM per 100 cm^2 statement)

Wipe test will be read on the uptake system probe with NaI(Tl) right cylindrical crystal. The LLD will be set at 20-50 keV and the ULD set at 999 keV. A background reading will be recorded with each set of wipe tests.

CONTROL NO. 78231

APPENDIX J

WASTE DISPOSAL

Note: In view of the recent problems with shallow-land burial sites used by commercial waste disposal firms, NRC is encouraging its licensees to reduce the volume of wastes sent to these facilities. Important steps in volume reduction are to segregate radioactive from nonradioactive waste, to hold short-lived radioactive waste for decay in storage, and to release certain materials in the sanitary sewer in accordance with §20.303 of 10 CFR Part 20.

1. Liquid waste will be disposed of (check as appropriate)

__X__ In the sanitary sewer system in accordance with §20.303 of 10 CFR Part 20.

_____ By commercial waste disposal service (see also Item 4 below).

_____ Other (specify): _____

2. Mo-99/Tc-99m generators will be (check as appropriate)

_____ Returned to the manufacturer for disposal.

__X__ Held for decay* until radiation levels, as measured in a low background area with a low-level survey meter and with all shielding removed, have reached background levels. All radiation labels will be removed or obliterated, and the generators will be disposed of as normal trash.**

_____ Disposed of by commercial waste disposal service (see also Item 4 below).

_____ Other (specify): _____

3. Other solid waste will be (check as appropriate)

__X__ Held for decay* until radiation levels, as measured in a low background area with a low-level survey meter and with all shielding removed, have reached background levels. All radiation labels will be removed or obliterated, and the waste will be disposed of in normal trash.

_____ Disposed of by commercial waste disposal service (see also Item 4 below).

__x*__ see below Other (specify): _____

4. The commercial waste disposal service used will be

_____
(Name) (City, State)

NRC/Agreement State License No. _____

*Be sure that waste storage areas were described in Item 11 and that they are surveyed periodically (Item 17).

**These generators may contain long-lived radioisotopic contaminants. Therefore, the generator columns will be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

*COMMENT: At present, most (used and unused) syringes, needles, and any other radioactive wastes are returned to the unit dose supplier for ultimate disposal at their facility.

CONTROL NO. 78231

APPENDIX K

RADIATION SAFETY PROCEDURES FOR THERAPEUTIC USE OF RADIOPHARMACEUTICALS*

1. All patients treated with I-131 or Au-198 will be placed in a private room that has a toilet. The large surfaces in the room and toilet areas that are more likely to be contaminated will be covered with absorbent pads or protective material as appropriate to the amounts of contamination to be expected. Attention should be given to objects likely to be touched by the patient, e.g., telephones, doorknobs, and other items that would be difficult to decontaminate. Plastic bags or wrappings that are waterproof and easily disposable should be used on the smaller items.

2. The patient's room will be properly posted or attended in accordance with §§20.203 or 20.204 of 10 CFR Part 20.

3. Surveys of the patient's room and surrounding areas will be conducted as soon as practicable after administration of the treatment dose. Exposure rates will be measured at the patient's bedside and 3 feet (or 1 m) from the patient after administration and at the entrance to the room. The Radiation Safety Officer or his designee will then determine how long a person may remain at these positions and will post these times on the patient's chart and on his door. The results of daily surveys will be used to recalculate permitted times, which will be posted on the patient's chart and on his door.

4. The form, Nursing Instructions for Patients Treated with Phosphorus-32, Gold-198, or Iodine-131 (or a similar form containing all the requested information), will be completed immediately after administration of the treatment dose. A copy will be posted on the patient's chart.

5. Radiation levels in unrestricted areas will be maintained less than the limits specified in paragraph 20.105(b) of 10 CFR Part 20.

6. All linens will be surveyed for contamination before being removed from the patient's room and, if necessary, will be held for decay.

7. Disposable plates, cups, eating utensils, tissue, surgical dressings, and other similar waste items will be placed in a specially designated container. The material will be collected daily by the Radiation Safety Officer or his designee, checked for contamination, and disposed of as normal or radioactive waste, as appropriate.

8. Nondisposable items used for these patients will be held in plastic bags in the patient's room and will be checked for contamination by the Radiation Safety Officer or his designee. Items may be returned for normal use, held for decay, or decontaminated, as appropriate.

9. If urine and vomitus from I-131 therapy patients are collected, they will be stored for decay in the radioactive waste storage area. Such stored wastes will be retained until they have reached background levels, as measured with a low-level survey meter. They will then be released to the sanitary sewer system.

10. Before a therapy patient's room is reassigned to another patient, the room will be surveyed for contamination and decontaminated if necessary, and all radioactive waste and waste containers will be removed.

11. Nursing Instructions

    a. Nurses should spend only that amount of time near the patient required for ordinary nursing care. Special restrictions may be noted on the precaution sheet on the patient's chart. Nurses should read these restrictions before administering to the patients. Call the Nuclear Medicine Department or the Radiation Safety Officer with any questions about the care of these patients. Nursing personnel who attend the patient will wear personnel monitoring devices as advised by the Radiation Safety Office.

    b. Visitors will be limited to those 18 years of age or over unless other instructions are noted on the precaution sheet on the patient's chart.

    c. Patients must remain in bed while visitors are in the room and visitors should remain at least 3 feet (or 1 m) from the patient.

    d. Patients containing radioactive materials are to be confined to their rooms except for special medical or nursing purposes approved by the Nuclear Medicine Department.

    e. No nurse, visitor, or attendant who is pregnant should be permitted in the room of a patient who has received a therapeutic amount of radioactivity until the patient no longer presents a radiation hazard. Female visitors should be asked whether they are pregnant.

    f. Attending personnel should wear rubber or disposable plastic gloves when handling urinals,

* Be sure to submit a complete response to Item 19b in addition to referencing procedures in Appendix K.

CONTROL NO. 7823

bedpans, emesis basins, or other containers having any material obtained from the body of the patient. Wash gloves before removing and then wash hands. The gloves should be left in the patient's room in the designated waste container. These gloves need not be sterile or surgical in type.

g. Disposable items should be used in the care of these patients, whenever possible. These items should be placed in the designated waste container. Contact the Radiation Safety Officer or his designee for proper disposal of the contents of the designated waste container.

h. All clothes and bed linens used by the patient should be placed in the laundry bag provided and should be left in the patient's room to be checked by the Radiation Safety Officer or his designee.

i. All nondisposable items should be placed in a plastic bag and should be left in the patient's room to be checked by the Radiation Safety Officer or his designee.

j. Surgical dressings should be changed only as directed by the physician. Au-198 leaking from a puncture wound may stain the dressings dark red or purple. Such dressings should not be discarded but should be collected in plastic bags and turned over to the Radiation Safety Officer or his designee. Handle these dressings only with tongs or tweezers. Wear disposable gloves.

k. For I-131 patients: *

(1) To the degree possible with cooperative patients, urine will be collected in special containers provided by the Radiation Safety Officer or his designee. The patient should be encouraged to collect his own urine in the container. If the patient is bedridden, a separate urinal or bed pan should be provided. The urinal or bed pan should be flushed several times with hot soapy water after use.

(2) If the nurse helps to collect the excreta, disposable gloves should be worn. Afterward, hands should be washed with the gloves on and again after the gloves are removed. The gloves should be placed in the designated waste container for disposal by the Radiation Safety Officer or his designee.

(3) Disposable plates, cups, and eating utensils will be used by patients who are treated with I-131.

(4) Vomiting within 24 hours after oral administration, urinary incontinence, or excessive sweating within the first 48 hours may result in contamination of linen and floor. In any situation where the patient's room may be contaminated or if radioactive urine and/or feces is spilled during collection, call the Radiation Safety Officer or his designee, Ext. _____. Meanwhile, handle all contaminated material with disposable gloves and avoid spreading contamination.

(5) Keep all contaminated wastes and vomitus in plastic bags in the patient's room for disposal by the Radiation Safety Officer or his designee. Feces need not be routinely saved unless ordered on the chart. The same toilet should be used by the patient at all times and it should be well flushed (3 times). The Radiation Safety Officer will establish procedures for disposal of wastes (see Item 12 below).

l. If a nurse, attendant, or anyone else knows or suspects that his or her skin or clothing, including shoes, is contaminated, notify the Radiation Safety Officer or his designee immediately. This person should remain in an area adjacent to the patient's room and should not walk about the hospital. If the hands become contaminated, wash them immediately with soap and water.

m. If a therapy patient should need emergency surgery or should die, notify the Radiation Safety Officer or the Nuclear Medicine Department immediately.

n. When the patient is discharged, call the Radiation Safety Officer or his designee or the Nuclear Medicine Department and request that the room be surveyed for contamination before remaking the room.

12. Waste Disposal

When contaminated wastes are transported to the Waste Storage/Disposal area, precautions will be taken to minimize external irradiation of personnel. Stored wastes will be shielded to maintain exposure to personnel in restricted and unrestricted areas ALARA.

* Urine will not be collected, as allowed in 10 CFR 20.303, exempting patient excreta.

CONTROL NO. 78231

ITEM 19

Date _____

NURSING INSTRUCTIONS FOR PATIENTS TREATED WITH PHOSPHORUS-32, GOLD-198, OR IODINE-131

Patient's Name: _____

Room No.: _____ Physician's Name: _____

Radioisotope Administered: _____

Date and Time of Administration: _____

Dose Received: _____ Method of Administration: _____

Exposure Rates in mR/hr

Date	3 feet from bed	10 feet from bed

(Comply with all checked items)

_____ 1. Visiting time permitted: _____

_____ 2. Visitors must remain _____ from patient.

_____ 3. Patient may not leave room.

_____ 4. Visitors under 18 are not permitted.

_____ 5. Pregnant visitors are not permitted.

_____ 6. Film or TLD badges must be worn.

_____ 7. Pocket chambers will be worn for supplementary personnel monitoring of individual tasks.

_____ 8. Tag the following objects and fill out the tag:

_____ door _____ chart

_____ bed _____ wrist

_____ 9. Disposable gloves must be worn while attending patient.

_____ 10. Patient must use disposable utensils.

_____ 11. All items must remain in room until approved for removal by the Radiation Safety Officer or his designee.

_____ 12. Smoking is not permitted.

_____ 13. Room is not to be released to Admitting Office until approved by the Radiation Safety Officer or his designee.

_____ 14. Other instructions.

In case of an emergency contact:

RSO _____

Name On-duty/Off-duty Telephone Numbers

CONTROL NC

4. EMERGENCY PROCEDURES

A. Notify persons in the room that a release has occurred.

B. All persons should vacate the room at once.

C. Close the room door(s) to prevent entry.

D. Notify the Radiation Safety Officer immediately.

E. Re-enter the room(s) after 23 minutes (5 turnovers of room air).

F. Perform an exposure rate survey with a GM survey meter.

5. AIR CONCENTRATIONS OF XE-133 IN RESTRICTED AREAS

A. Activity used (A) = 10 mCi x 10 exams/wk x 1E3 uCi/mCi
= 1E5 uCi/wk

B. Loss rate (f) = 0.20

C. Ventilation required (V) = (A x f) / (1E-5 uCi/ml)

$$= \frac{1E5 \text{ uCi/wk} \times 0.20}{1E\text{-}5 \text{ uCi/ml}}$$

$$= 2.0E9 \text{ ml/wk}$$

Assuming a 40-hour week:

$$V = \frac{(2.0E9 \text{ ml/wk}) / (40 \text{ h/wk})}{1.7E6 \text{ ml/h-CFM}}$$

$$= 29.4 \text{ CFM}$$

Thus, the airflow in the area of interest, 654 CFM in the Hot Lab and 654 CFM in the Imaging Department , is adequate.

6. AIR CONCENTRATIONS OF XE-133 IN UNRESTRICTED AREAS

A. Charcoal-trap adsorption (Reg. Guide 10.8, Appendix M, 6.b) via the Pulmonex Model 130-500 Xenon Delivery and Trap System.

B. Ventilation required (V) = $\frac{(1E5 \text{ uCi/wk}) / 0.20}{3E\text{-}7 \text{ uCi/ml}}$

$$= 6.67E10 \text{ ml/wk}$$

ITEM 21

22341 West Eight Mile Road
ADDRESS

APPENDIX M

INFORMATION IN SUPPORT OF XE-133 USE

1. QUANTITIES TO BE USED

A. Patient information

(1). 10 studies per week
(2). 10 milliCuries (average) per study

B. 200 milliCuries possession limit

2. USE AND STORAGE AREAS

A. Xenon-133 will be stored in the Storage Area of the Hot Lab and used (i.e., administration, imaging, and trapping/exhaust) in the Imaging Area.

B. Ventilation: A(n) 654 CFM Exhaust in the Hot Lab and 654 CFM Exhaust system in the Imaging Department deliver(s) air directly to OUTSIDE air on the facility roof, carrying a major portion of any Xe-133 contamination, and is (are) situated well away from any intake vents (30 feet minimum). Total exhaust is therefore 1308 CFM. Total supply is 366 CFM. A 10% negative pressure will be maintained at all times. Airflow will therefore come from the hallway via the door(s). No air is recirculated.

C. In the case of exhaust fan shutdown, Xe-133 studies will not be performed.

3. PROCEDURES FOR ROUTINE USE

A. When stored in the Hot Lab, Xe-133 is contained in unit dose ampules inside 1/8" lead shipping tubes behind lead bricks. Individual doses will be assayed in the dose calibrator and admininstered using the NEN Calidose Gas Dispensing System. The seal will be broken only in the Imaging Area. Thus, no significant leakage is expected in the Hot Lab Area.

B. Xe-133 will be administered to the patient and collected using the Pulmonex Model 130-500 Xenon Delivery and Trap System. For each patient study, the technologist will check the tubing of the xenon delivery system for defects and will familiarize the patient with the study.

C. Nose clamps will be used to reduce leakage.

CONTROL NO. 78231

Assuming a 168-hour week:

$$V = \frac{(6.67E10\ ml/week)\ /\ (168\ h\text{-}wk)}{1.7E6 ml/h\text{-}CFM}$$

$$= 233.4\ CFM$$

Thus, 654 CFM in the Hot Lab and 654 CFM in the Imaging Department is adequate. Duct(s) on-time will be approximated from the following equation and recorded:

$$\text{Duct(s) On-Time} = \frac{(n/10) \times 168h \times 233.4\ CFM}{1308\ CFM}$$

where:
n = number of 10 mCi-equivalent patient studies

C. Trap monitoring

(1) Effluent from the trap exhaust will be collected in a test balloon weekly and counted on a Gamma Camera with the collimator removed and the PHA set for Xe-133. The procedure for xenon trap evaluation is included. Care will be taken to assure that no extraneous radiation sources interfere with the measurements. Given a 10 mCi dose and assuming a 95% trapping efficiency and no residual Xe-133, a 500 uCi action level for trap removal is deemed reasonable. However, experience dictates that effluent is significantly less than 500 uCi in properly operating systems. Thus, an action level of 200 uCi will be set, which is a small fraction of the assumed 20% leakage from all sources.

(2) Saturated filters will be sealed (per manufacturer's instructions) to prevent leakage. These will be then stored in the "Decay-to-Background" Radioactive Waste Storage Area or returned to the supplier.

(3) An optional method for checking effluent from the trap exhaust will be used if a XenAlert Xe-133 Room Air and Trap Monitor System is purchased. This device will be used weekly and will be calibrated annually as outlined in the manual provided with each unit. A similar action level (mentioned above) will be used.

(4) Velometer readings will be taken semi-annually to assure air flow through supply and exhausts systems have remained stable.

ITEM 21

41935 West Twelve Mile Road
ADDRESS

APPENDIX M

INFORMATION IN SUPPORT OF XE-133 USE

1. QUANTITIES TO BE USED

A. Patient information

(1). 10 studies per week
(2). 10 milliCuries (average) per study

B. 200 milliCuries possession limit

2. USE AND STORAGE AREAS

A. Xenon-133 will be stored in the Storage Area of the Hot Lab and used (i.e., administration, imaging, and trapping/exhaust) in the Imaging Area.

B. Ventilation: A(n) 120 CFM Exhaust in the Hot Lab and 234 CFM Exhaust system in the Imaging Department deliver(s) air directly to OUTSIDE air on the facility roof, carrying a major portion of any Xe-133 contamination, and is (are) situated well away from any intake vents (30 feet minimum). Total exhaust is therefore 354 CFM. Total supply is 213 CFM. A 10% negative pressure will be maintained at all times. Airflow will therefore come from the hallway via the door(s). No air is recirculated.

C. In the case of exhaust fan shutdown, Xe-133 studies will not be performed.

3. PROCEDURES FOR ROUTINE USE

A. When stored in the Hot Lab, Xe-133 is contained in unit dose ampules inside 1/8" lead shipping tubes behind lead bricks. Individual doses will be assayed in the dose calibrator and admininstered using the NEN Calidose Gas Dispensing System. The seal will be broken only in the Imaging Area. Thus, no significant leakage is expected in the Hot Lab Area.

B. Xe-133 will be administered to the patient and collected using the Pulmonex Model 130-500 Xenon Delivery and Trap System. For each patient study, the technologist will check the tubing of the xenon delivery system for defects and will familiarize the patient with the study.

C. Nose clamps will be used to reduce leakage.

CONTROL NO. 78231

4. EMERGENCY PROCEDURES

A. Notify persons in the room that a release has occurred.

B. All persons should vacate the room at once.

C. Close the room door(s) to prevent entry.

D. Notify the Radiation Safety Officer immediately.

E. Re-enter the room(s) after 48 minutes (5 turnovers of room air).

F. Perform an exposure rate survey with a GM survey meter.

5. AIR CONCENTRATIONS OF XE-133 IN RESTRICTED AREAS

A. Activity used (A) = 10 mCi x 10 exams/wk x 1E3 uCi/mCi
= 1E5 uCi/wk

B. Loss rate (f) = 0.20

C. Ventilation required (V) = (A x f) / (1E-5 uCi/ml)

$$= \frac{1E5 \text{ uCi/wk} \times 0.20}{1E\text{-}5 \text{ uCi/ml}}$$

$$= 2.0E9 \text{ ml/wk}$$

Assuming a 40-hour week:

$$V = \frac{(2.0E9 \text{ ml/wk}) / (40 \text{ h/wk})}{1.7E6 \text{ ml/h-CFM}}$$

$$= 29.4 \text{ CFM}$$

Thus, the airflow in the area of interest, 120 CFM in the Hot Lab and 234 CFM in the Imaging Department , is adequate.

6. AIR CONCENTRATIONS OF XE-133 IN UNRESTRICTED AREAS

A. Charcoal-trap adsorption (Reg. Guide 10.8, Appendix M, 6.b) via the Pulmonex Model 130-500 Xenon Delivery and Trap System.

B. Ventilation required (V) = $\frac{(1E5 \text{ uCi/wk}) / 0.20}{3E\text{-}7 \text{ uCi/ml}}$

$$= 6.67E10 \text{ ml/wk}$$

Assuming a 168-hour week:

$$V = \frac{(6.67E10\ ml/week)\ /\ (168\ h\text{-}wk)}{1.7E6 ml/h\text{-}CFM}$$

$$= 233.4\ CFM$$

Thus, 120 CFM in the Hot Lab and 234 CFM in the Imaging Department is adequate. Duct(s) on-time will be approximated from the following equation and recorded:

$$\text{Duct(s) On-Time} = \frac{(n/10) \times 168h \times 233.4\ CFM}{354\ CFM}$$

where:
n = number of 10 mCi-equivalent patient studies

C. Trap monitoring

(1) Effluent from the trap exhaust will be collected in a test balloon weekly and counted on a Gamma Camera with the collimator removed and the PHA set for Xe-133. The procedure for xenon trap evaluation is included. Care will be taken to assure that no extraneous radiation sources interfere with the measurements. Given a 10 mCi dose and assuming a 95% trapping efficiency and no residual Xe-133, a 500 uCi action level for trap removal is deemed reasonable. However, experience dictates that effluent is significantly less than 500 uCi in properly operating systems. Thus, an action level of 200 uCi will be set, which is a small fraction of the assumed 20% leakage from all sources.

(2) Saturated filters will be sealed (per manufacturer's instructions) to prevent leakage. These will be then stored in the "Decay-to-Background" Radioactive Waste Storage Area or returned to the supplier.

(3) An optional method for checking effluent from the trap exhaust will be used if a XenAlert Xe-133 Room Air and Trap Monitor System is purchased. This device will be used weekly and will be calibrated annually as outlined in the manual provided with each unit. A similar action level (mentioned above) will be used.

(4) Velometer readings will be taken semi-annually to assure air flow through supply and exhausts systems have remained stable.

PROCEDURE FOR XENON TRAP EVALUATION

METHOD

1. Determine the background count rate in counts per minute by counting for five minutes and dividing the total counts by (5) five.

2. Place a known activity of xenon-133 (50-100 uCi's) in front of an uncollimated gamma camera at a fixed distance. The fixed distance should approximate the radius of the testing balloon. The window should be centered at the 81 keV photopeak.

3. Collect at least (1) one million counts from the xenon. Divide the total counts by the counting time to get the counts per minute from the source. Subtract the background counts per minute found in step 1.

4. Divide the counts per minute (CPM) determined in the previous step, by the known activity of xenon in the vial. This yields the efficiency (EF) of the camera in CPM/uCi.

5. Attach the test balloon to the exhaust of the xenon trap and fill the balloon with air which has passed through the filter. The radius of the balloon should be approximately the same distance as between source and crystal outlined in step 2.

6. Place the balloon in front of the gamma camera so that the edge of the balloon just touches the crystal. Count for two minutes. Divide by (2) two to get the counts per minute, and subtract the background counts per minute found in step 1.

7. Determine the activity in the balloon as follows:

   CPM(step 6)/EF(step 4) = activity in balloon

8. For subsequent patient studies, start at step 5 and proceed, using the previously calculated EF.

9. An action level of 100-200 uCi's should indicate possible change of trap charcoal.

CONTROL NO. 78231